FACTANKER · measured, cited, anchored official records connected

SEC EDGAR CompanyFacts fact · reporting period

NASUS PHARMA LTD.: xbrl:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

One fact, its scope and the complete path back to the official record.

Period: 2024-01-01 – 2024-06-30Status: currentProvenance attached

Cite: FACTANKER, https://factanker.com/fact/2c85c8d0-8e3e-4e3d-9841-acbc5628caf9

Reported value

$706.000k{"amount": 706000, "currency": "USD"}
Entity
NASUS PHARMA LTD.
Metric
xbrl:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
Period
2024-01-01 – 2024-06-30
Status
current
Source
SEC EDGAR CompanyFacts

Provenance

Official reference0001493152-25-029210 · Open the official SEC filing →
Source licenseUS-PD-17USC105
Retrieved2026-08-19T19:06:39.902333+02:00
Raw response SHA-256f7bde1a401b286c74a2fd824ee1df541…
History
  • no predecessors — first report

Why this page exists

The UUID above is the stable citation anchor: it never changes, and corrections supersede rather than overwrite. Cite the URL and any reader — human or machine — can verify the value against the official filing.